Compare · CLPT vs MDLN
CLPT vs MDLN
Side-by-side comparison of ClearPoint Neuro Inc. (CLPT) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLPT and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $58.42B, about 174.3x CLPT ($335.2M).
- Over the past year, CLPT is down 18.5% and MDLN is up 9.7% - MDLN leads by 28.2 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- MDLN has more recent analyst coverage (25 ratings vs 4 for CLPT).
- Company
- ClearPoint Neuro Inc.
- Medline Inc.
- Price
- $11.33+1.34%
- $44.73+0.58%
- Market cap
- $335.2M
- $58.42B
- 1M return
- +23.96%
- +1.56%
- 1Y return
- -18.49%
- +9.69%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 5
- 5
- Recent ratings
- 4
- 25
ClearPoint Neuro Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.
Latest CLPT
- ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
- SEC Form DEFA14A filed by ClearPoint Neuro Inc.
- ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
- ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
- SEC Form DEF 14A filed by ClearPoint Neuro Inc.
- SEC Form 4 filed by Fletcher R John
- SEC Form 4 filed by Girin Pascal E R
- SEC Form 4 filed by Richards Timothy T.
- Amendment: SEC Form SCHEDULE 13G/A filed by ClearPoint Neuro Inc.
- SEC Form 4 filed by Burnett Joseph
Latest MDLN
- SEC Form DEFA14A filed by Medline Inc.
- SEC Form DEF 14A filed by Medline Inc.
- Medline announces first-in-healthcare AI robotics partnership with Symbotic
- Medline to report first quarter 2026 results on May 6, 2026
- Medline launches custom product fulfillment technology called Pick Pack Pro™
- Medline recognizes manufacturing facilities with Golden Cone Safety Award
- Medline receives HIRC Member Choice Awards for supply chain achievement and renews Transparency Badge distinction
- Director Healy Patrick J acquired 577,510 shares, increasing direct ownership by 73% to 1,208,159 units (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,058,524,148 worth of shares (26,131,237 units at $40.51) and disposed of 2,088,086 shares (SEC Form 4)
- Large owner Cp Circle Ml Holdco Gp, Llc sold $1,070,339,440 worth of shares (26,105,840 units at $41.00) and disposed of 2,113,483 shares (SEC Form 4)